GLP-1 Agonist Solid Compositions with SNAC Salt for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human GLP-1 agonists have low oral bioavailability, requiring specific absorption enhancers for detection in plasma after oral administration, and there is a need for an optimized pharmaceutical composition for oral administration of GLP-1 agonists.
Innovation Solution
A solid composition comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino) caprylic acid, where the amount of the salt is at least 0.6 mmol, optimizing the exposure and bioavailability of the GLP-1 agonist for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If GLP-1 agonist is administered orally without absorption enhancer, then formulation is simple, but bioavailability is very low and GLP-1 cannot be detected in plasma
Solution Approach 1:
The patent introduces SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) as an intermediary substance that facilitates the absorption of GLP-1 agonist across the gastrointestinal barrier. SNAC acts as a delivery vehicle that temporarily complexes with the peptide, protects it from degradation, and enhances its permeability through intestinal membranes, enabling systemic circulation without requiring complex formulation technologies
Solution Approach 2:
The patent optimizes the molar ratio parameter between SNAC and GLP-1 agonist (specifically 3:1 to 10:1 ratio) to achieve maximum bioavailability enhancement. By adjusting this critical parameter, the formulation transforms from ineffective to highly efficient in delivering the active ingredient systemically
2Reliability
If specific amount of absorption enhancer is used, then bioavailability improves, but formulation complexity increases
Solution Approach 1:
The patent establishes specific quantitative parameters for SNAC dosage (at least 0.6 mmol, preferably at least 0.8 mmol) and molar ratio to GLP-1 agonist (3:1 to 10:1). These defined parameters create a standardized formulation approach that balances enhanced bioavailability with manufacturing feasibility, avoiding overly complex formulation strategies
Solution Approach 2:
The patent isolates and focuses on a single key absorption enhancer (SNAC) rather than using multiple complex delivery systems. By extracting the essential function of absorption enhancement to one well-characterized ingredient with defined dosage, the formulation achieves improved bioavailability while maintaining relative simplicity in composition and manufacturing
Data Source
AI summary
The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.